[1] del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci. 2008;35(3):161-174.
[2] Dickens D, Webb SD, Antonyuk S, Giannoudis A, Owen A, Rädisch S, Hasnain SS, et al. Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013;85(11):1672-1683.
[3] Shi L, Luo W, Huang W, Huang S, Huang G. Downregulation of L-type amino acid transporter 1 expression inhibits the growth, migration and invasion of gastric cancer cells. Oncol Lett. 2013;6(1):106-112.
[4] Patel M, Dalvi P, Gokulgandhi M, Kesh S, Kohli T, Pal D, Mitra AK. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells. Int J Pharm. 2013;443(1-2):245-253.
[5] Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, et al. Hematopoietic stem cell transplantation for multiple myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(7):1155-1166.
[6] Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol. 2007;64(2):151-164.
[7] Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, et al. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clin Pharmacol Ther. 2017;102(3): 511-519.
[8] Giglia J, White M, Hart A, Toro J, Freytes C, Holt C, et al. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2014;20(7):1014-1020.
[9] Beijers AJ, Vreugdenhil G, Oerlemans S, Eurelings M, Minnema MC, Eeltink CM, et al. Chemotherapy-induced neuropathy in multiple myeloma: Influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer. 2016;24(6):2411-2420.
[10] Guttuso T, Jr. Gabapentin's anti-nausea and anti-emetic effects: A review. Exp Brain Res. 2014;232(8):2535-2539.
[11] National Cancer Institute. Common terminology criteria for adverse events (CTCAE), v4.03. 2010. National Cancer Institute, Bethesda, MD.
[12] Cruz FM, de Iracema Gomes Cubero D, Taranto P, Lerner T, Lera AT, da Costa Miranda M, et al. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: A pilot study. Support Care Cancer. 2012;20(3):601-606.
[13] Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesth Analg. 2007;104(6):1545-1556.
[14] Kuhne A, Kaiser R, Schirmer M, Heider U, Muhlke S, Niere W, et al. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet Genomics. 2007;17(7):505-517.
[15] Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360-376.